Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.56 |
| ▸ | CDC25B | P30305 | 8/20 | 0.56 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.56 |
| ▸ | SSTR2 | P30874 | 5/20 | 0.56 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.56 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.56 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324513 | 1.00 | PTPN1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL2290690 | 1.00 | PTPN1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL6544669 | 1.00 | PTPN1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL14074554 | 1.00 | PTPN1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL12380696 | 1.00 | PTPN1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL6544666 | 1.00 | PTPN1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL12380719 | 0.97 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL12380725 | 0.93 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL2292522 | 0.93 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL6889266 | 0.93 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | ENTEROME (FR) | 2020-01-28 | — | — | US | disclosed |
| EP-3331893-B1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | ENTEROME (FR) | 2019-05-22 | — | — | EP | disclosed |
| US-20180235991-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | NANTES UNIVERSITE (FR) | 2018-08-23 | — | — | US | disclosed |
| US-7989602-B2 | having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity; asthma, allergic rhinitis, dermatitis, psoriasis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus | THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | UNIVERSITY OF OTAGO (NZ) | 2008-10-09 | — | — | US | disclosed |
| US-6908989-B2 | Process for the production of perbenzylated 1-O-glycosides | SCHERING AG (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-1261614-B1 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-6545135-B2 | Alkylation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | MAN1B1, STT3B, OSTC | PTPN1 1928/4885CDC25B 1637/4885SSTR1 4350/4885 |
| US-20180235991-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | FPR3, CCR3, RXFP3 | PTPN1 3404/4885CDC25B 4489/4885SSTR1 1105/4885 |
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | FPR3, CCR3, RXFP3 | PTPN1 3404/4885CDC25B 4489/4885SSTR1 1105/4885 |
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | ALG1, PAG1, SIGLEC7 | PTPN1 1017/4885CDC25B 1097/4885SSTR1 4558/4885 |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | PTPN1 2526/4885CDC25B 1245/4885SSTR1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.